Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OncoVex GM-CSF: BioVex began a U.K. Phase I trial in 18 patients with solid tumors.

BioVex Ltd., Oxford, U.K.
Product: OncoVex

Read the full 60 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE